(NEXSTAR) – Americans looking to get a booster shot against the coronavirus this fall don’t just have one new option – they’ve got two. Both Moderna and Pfizer have a new FDA-authorized COVID-19 ...
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.
Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That ...
Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...
Pfizer has made important moves in the past few years that could pay off down the line. It earned approval for several medicines and vaccines, including Litfulo, a therapy for alopecia areata, and ...
Despite a U.S. factory mixup, more Johnson & Johnson doses are becoming available in the U.S., marking the only single-shot vaccine option. So how effective is it and how does it compare to the Pfizer ...
Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses the differences between ...
The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results